Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Nausheen Ahmed & Mehdi Hamadani. (2021) Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. Expert Review of Anticancer Therapy 21:12, pages 1313-1320.
Read now
Read now
Articles from other publishers (20)
Yujia Peng, Yiran Tao, Ya Zhang, Jiaxing Wang, Jinliang Yang & Yuxi Wang. (2022)
CD25
: A potential tumor therapeutic target
. International Journal of Cancer 152:7, pages 1290-1303.
Crossref
Crossref
Beverly A. Teicher & Joel Morris. (2022) Antibody-drug Conjugate Targets, Drugs, and Linkers. Current Cancer Drug Targets 22:6, pages 463-529.
Crossref
Crossref
Mario Fernández-Ruiz. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
3
15
.
Yurou Chu, Xiangxiang Zhou & Xin Wang. (2021) Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Hamza Hashmi, Alicia Darwin & Taiga Nishihori. (2021) Therapeutic roles of antibody drug conjugates (ADCs) in relapsed/refractory lymphomas. Hematology/Oncology and Stem Cell Therapy.
Crossref
Crossref
Tomohiro Kinoshita, Kiyohiko Hatake, Kazuhito Yamamoto, Yusuke Higuchi, Satsuki Murakami, Yasuhito Terui, Masahiro Yokoyama, Dai Maruyama, Shinichi Makita, Yukari Hida, Tomohisa Saito & Kensei Tobinai. (2021) Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. Japanese Journal of Clinical Oncology 51:1, pages 70-77.
Crossref
Crossref
Shaheda Parveen, Saman Fatima, Syed Naved Quadri, Sarwar Beg & M.Z. Abdin. 2021. Nanoformulation Strategies for Cancer Treatment. Nanoformulation Strategies for Cancer Treatment
131
152
.
Colby S. Shemesh, Priya Agarwal, Tong Lu, Calvin Lee, Randall C. Dere, Xiaobin Li, Chunze Li, Jin Y. Jin, Sandhya Girish, Dale Miles & Dan Lu. (2020) Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology 85:5, pages 831-842.
Crossref
Crossref
Nahum Puebla-Osorio, Paolo Strati & Sattva S. Neelapu. 2020. Follicular Lymphoma. Follicular Lymphoma
65
82
.
Dalma Deak, Cristina Pop, Alina-Andreea Zimta, Ancuta Jurj, Alexandra Ghiaur, Sergiu Pasca, Patric Teodorescu, Angela Dascalescu, Ion Antohe, Bogdan Ionescu, Catalin Constantinescu, Anca Onaciu, Raluca Munteanu, Ioana Berindan-Neagoe, Bobe Petrushev, Cristina Turcas, Sabina Iluta, Cristina Selicean, Mihnea Zdrenghea, Alina Tanase, Catalin Danaila, Anca Colita, Andrei Colita, Delia Dima, Daniel Coriu, Hermann Einsele & Ciprian Tomuleasa. (2019) Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. Frontiers in Immunology 10.
Crossref
Crossref
Francesca Bonello, Roberto Mina, Mario Boccadoro & Francesca Gay. (2019) Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers 12:1, pages 15.
Crossref
Crossref
Lazaros J. Lekakis & Craig H. Moskowitz. (2019) The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy. HemaSphere 3:6, pages e295.
Crossref
Crossref
María-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, Meral Beksac, Joan Bladé, Mario Boccadoro, Michele Cavo, Michel Delforge, Meletios A. Dimopoulos, Thierry Facon, Catarina Geraldes, Hartmut Goldschmidt, Roman Hájek, Markus Hansson, Krzysztof Jamroziak, Merav Leiba, Tamás Masszi, Larisa Mendeleeva, Michael O’Dwyer, Torben Plesner, Jesús F. San-Miguel, Christian Straka, Niels W.C.J. van de Donk, Kwee Yong, Samo Zver, Philippe Moreau & Pieter Sonneveld. (2019) Insights on Multiple Myeloma Treatment Strategies. HemaSphere 3:1, pages e163.
Crossref
Crossref
Olga Kutova, Evgenii Guryev, Evgeniya Sokolova, Razan Alzeibak & Irina Balalaeva. (2019) Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency. Cancers 11:1, pages 68.
Crossref
Crossref
K.Y. Manoilov. (2018) BIOLOGICAL PROPERTIES AND MEDICAL APPLICATION OF DIPHTHERIA TOXIN DERIVATIVES. Biotechnologia Acta 11:3, pages 27-46.
Crossref
Crossref
L. Drgona, C. Gudiol, S. Lanini, B. Salzberger, G. Ippolito & M. Mikulska. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clinical Microbiology and Infection 24, pages S83-S94.
Crossref
Crossref
M. Fernández-Ruiz, Y. Meije, O. Manuel, H. Akan, J. Carratalà, J.M. Aguado & J. Delaloye. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). Clinical Microbiology and Infection 24, pages S2-S9.
Crossref
Crossref
Cédric Rossi, Marie-Lorraine Chrétien & René-Olivier Casasnovas. (2018) Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review. Targeted Oncology 13:3, pages 287-308.
Crossref
Crossref
Fu Li, May Kung Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere-Douglass, Lucy Pan, Ashley Cronkite, Django Sussman, Kerry Klussman, Michelle Ulrich, Martha E. Anderson, Ivan J. Stone, Weiping Zeng, Mechthild Jonas, Timothy S. Lewis, Maitrayee Goswami, Sa A. Wang, Peter D. Senter, Che-Leung Law, Eric J. Feldman & Dennis R. Benjamin. (2018) Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia. Molecular Cancer Therapeutics 17:2, pages 554-564.
Crossref
Crossref
Nancy L Goicochea, Maria Garnovskaya, Mary G Blanton, Grace Chan, Richard Weisbart & Michael B Lilly. (2017) Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy†. Protein Engineering, Design and Selection 30:12, pages 785-793.
Crossref
Crossref